Clinical Investigation
Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer

https://doi.org/10.1016/j.ijrobp.2007.04.036Get rights and content

Purpose

In lung cancer, stage is an important prognostic factor for disease progression and survival. However, stage may be simply a surrogate for underlying tumor burden. Our purpose was to assess the prognostic value of tumor burden measured by 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) imaging.

Patients and Methods

We identified 19 patients with lung cancer who had staging PET-CT scans before any therapy, and adequate follow-up (complete to time of progression for 18, and death for 15 of 19). Metabolically active tumor regions were segmented on pretreatment PET scans semi-automatically using custom software. We determined the relationship between times to progression (TTP) and death (OS) and two PET parameters: total metabolic tumor volume (MTV), and standardized uptake value (SUV).

Results

The estimated median TTP and OS for the cohort were 9.3 months and 14.8 months. On multivariate Cox proportional hazards regression analysis, an increase in MTV of 25 ml (difference between the 75th and 25th percentiles) was associated with increased hazard of progression and of death (5.4-fold and 7.6-fold), statistically significant (p = 0.0014 and p = 0.001) after controlling for stage, treatment intent (definitive or palliative), age, Karnofsky performance status, and weight loss. We did not find a significant relationship between SUV and TTP or OS.

Conclusions

In this study, high tumor burden assessed by PET MTV is an independent poor prognostic feature in lung cancer, promising for stratifying patients in randomized trials and ultimately for selecting risk-adapted therapies. These results will need to be validated in larger cohorts with longer follow-up, and evaluated prospectively.

Lung cancer
Positron emission tomography (PET)
Metabolic tumor volume (MTV)
Prognostic factors
Automatic image analysis

Cited by (0)

Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

Presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), October 16–20, 2005, Denver, CO.

Conflict of interest: none.

View Abstract